Holen Sie sich die Stockscreener-App
13.55
0.80%
-0.125
Handel nachbörslich:
13.55
-0.005
-0.04%
Schlusskurs vom Vortag:
$13.68
Offen:
$13.765
24-Stunden-Volumen:
933.78K
Relative Volume:
0.65
Marktkapitalisierung:
$1.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-185.15M
KGV:
-6.6928
EPS:
-2.0253
Netto-Cashflow:
$-148.72M
1W Leistung:
+3.59%
1M Leistung:
-12.62%
6M Leistung:
-51.74%
1J Leistung:
+169.25%
1-Tages-Spanne:
$13.28
$13.92
1-Wochen-Bereich:
$13.16
$14.29
52-Wochen-Spanne:
$3.89
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
13.56 | 1.19B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy - Moomoo
Olema Oncology and Bayer Partner on Clinical Trial to Evaluate OP-3136 and NUBEQA® in Metastatic Castration-Resistant Prostate Cancer 1 - Minichart
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial - GuruFocus
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
Olema oncology announces clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with Nubeqa® (darolutamide) in metastatic castration-resistant prostate cancer - marketscreener.com
Olema Oncology (NASDAQ: OLMA) inks Bayer trial deal for OP-3136 combo - Stock Titan
New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA - Stock Titan
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - Yahoo Finance
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Olema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 study - MSN
Olema Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:OLMA - Benzinga
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study - Yahoo Finance
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Olema Oncology Reports Promising Phase 1 Results for OP-3136 KAT6 Inhibitor in Advanced Solid Tumors at 2026 ASCO Meeting 12 - Minichart
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - Sahm
Olema reports phase 1 data for cancer drug OP-3136 By Investing.com - Investing.com South Africa
Olema reports phase 1 data for cancer drug OP-3136 - Investing.com UK
Olema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid Tumors - Quiver Quantitative
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data - Stock Titan
Early cancer trial sees tumor shrinkage in 13 of 19 on Olema drug - Stock Titan
Olema Pharmaceuticals (OLMA) Valuation After Encouraging New OP-3136 Phase 1 Data - Sahm
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
Breast cancer-focused Olema plans 3 investor talks across May and June - Stock Titan
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $52 - Moomoo
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Olema Pharmaceuticals (OLMA) Deepens Trial Spend With Ample Cash Buffer Is Its Risk-Reward Now Clearer? - Sahm
Olema Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Bain Capital (OLMA) discloses 8.2% position including pre-funded warrant - Stock Titan
Janus Henderson (NASDAQ: OLMA) discloses 7.11M shares, 8.2% stake - Stock Titan
Olema: The Market Overreacted To Roche's SERD Failure - Seeking Alpha
Legal operations leadership role opens as Olema Pharmaceuticals launches search for senior manager - Traders Union
Olema Oncology (OLMA) Gains Attention with Upcoming Clinical Res - GuruFocus
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $23 to $48 - Moomoo
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
OLMA Maintained by Guggenheim -- Price Target Lowered to $35.00 - GuruFocus
OpenAI pushed this startup out of San Francisco, but it found a brand-new space elsewhere - The Business Journals
Guggenheim cuts Olema Pharmaceuticals stock price target on trial timing By Investing.com - Investing.com Canada
TradingKey - TradingKey
Olema Pharmaceuticals Q1 Net Loss Widens - Moomoo
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Oncology (OLMA) Focuses on Advancing Breast Cancer Treatme - GuruFocus
How to Value Olema Pharmaceuticals (OLMA) After Q1 2026 Earnings - GuruFocus
Olema Oncology Announces Q1 2026 Financial Results and Upcoming Phase 3 Breast Cancer Trial Data - Minichart
Olema Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Olema Oncology Announces First Quarter 2026 Financial and Operating Results on May 12 - geneonline.com
Olema Pharmaceuticals Ended 1Q With $505.3M Cash, Equivalents, Marketable Securities >OLMA - Moomoo
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):